Eton Pharmaceuticals CBO Sells $3.23M in Stock After Option Exercise
ETON has more than doubled off its 52-week low of $13.085.
Summary
Eton Pharmaceuticals' Chief Business Officer, David Krempa, sold $3.23 million worth of common stock after exercising options, significantly reducing his direct holdings.
Key Events · Ownership and Investor Activity · ETON
-
Chief Business Officer Sells Shares
David Krempa, Chief Business Officer, sold 100,000 shares of common stock for a total value of $3,229,923.25. The sales occurred between May 22 and May 27, 2026, at prices ranging from $31.47 to $35.00 per share.
-
Option Exercise Precedes Sale
Prior to the sales, Mr. Krempa exercised options to acquire 87,794 shares of common stock for a total cost of $204,052.52, with exercise prices ranging from $1.37 to $3.58 per share.
-
Reduced Direct Holdings
Following these transactions, Mr. Krempa's direct ownership in Eton Pharmaceuticals decreased to 125,609 shares.
-
Timing Follows Positive News
This significant insider sale occurs after a period of strong company performance, including FDA approvals, product acquisitions, and robust Q1 2026 financial results, which led to a recent surge in the stock price.
Analysis · ETON · Life Sciences
Chief Business Officer David Krempa sold a significant portion of his holdings, totaling $3.23 million, after exercising options. This transaction, occurring after a period of strong financial results and a recent stock surge, represents an insider monetizing vested equity and reducing their direct ownership in the company.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.6% of the 1721 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETON was trading at $33.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $887.5M. The 52-week trading range was $13.09 to $35.66. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.